Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

BGM vs GLPG: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

GLPG Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 8–1 Matrix Metrics)

GLPG Overall Winner 6-Pillar Tally: BGM 1 – 3 GLPG (2 Tie) Matrix Metrics: BGM 1 – 8 GLPG

As of Nov 19, 2026, Galapagos NV (GLPG) is the stronger overall head-to-head candidate over BGM Group Ltd. Class A (BGM) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). BGM carries a Unified Composite Score of 59.6/100 (HOLD) at $8.00 (N/M Forward P/E, -23.4% operating margin), whereas GLPG carries 61.5/100 (BUY) at $27.73 (N/M Forward P/E, 88.0% operating margin).

  • Technical & Structure Timing Caution: BGM trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 53.8); meanwhile GLPG is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BGM vs GLPG
BGM NASDAQ
BGM Group Ltd. Class A Ordinary Shares
Pharmaceutical Preparations
$8.00
-1.6% 1D
Market Cap $108.6M
TTM Revenue $48M
Forward P/E N/M
Beta / 30D Vol 3.69β · 80% Vol
Unified Composite Score
59.6 / 100 HOLD
Tech 65.0 Fund 55.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (167.7% over 20 days), RSI 54
RSI-14: 53.8 · SMA20: $8.51 · SMA50: $5.25
GLPG NASDAQ Head-to-Head Winner
Galapagos NV
Pharmaceutical Preparations
$27.73
-3.75% 1D
Market Cap $1.9B
TTM Revenue $602M
Forward P/E N/M
Beta / 30D Vol 0.71β · 20% Vol
Unified Composite Score
61.5 / 100 BUY
Tech 45.0 Fund 52.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.7%), weak momentum, RSI 36
RSI-14: 36.5 · SMA20: $28.59 · SMA50: $30.32

6-Pillar Scorecard Institutional Category Breakdown (BGM 1 – 3 GLPG)

Columns: Metric · BGM · GLPG
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M 5.1x
PEG Ratio N/M N/M
EV / Revenue 2.3x 3.2x
2. Growth & Scale GLPG
Revenue Growth (YoY) +69.8% +1093.2%
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) $48M $602M
Market Cap $108.6M $1.9B
3. Profitability & Quality GLPG
Gross Margin 16.9% 56.0%
Operating Margin -23.4% 88.0%
Net Profit Margin -44.2% 28.8%
Return on Equity (ROE) -7.4% 10.4%
4. Balance Sheet & Cash Flow GLPG
Cash Generation (TTM) -$9.2M EBITDA $308M EBITDA
Cash Flow Margin -19.3% EBITDA Mgn 51.1% EBITDA Mgn
Net Cash / Leverage $59.55 Book/Sh · -7.4% ROE $2.90 Book/Sh · 10.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 35.2% (2nd %ile)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat BGM
OpEx & R&D Intensity 40.3% of Rev ($19M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BGM (1) vs GLPG (8)
Institutional Metric BGM GLPG Criterion Row Edge
Market Capitalization
Scale
$108.6M $1.9B Larger Scale GLPG
Trailing P/E Ratio
Valuation
N/M 5.1x Lower Multiple GLPG
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+69.8% +1093.2% Higher Growth GLPG
Operating Margin (TTM)
Profitability
-23.4% 88.0% Higher Margin GLPG
Net Profit Margin
Profitability
-44.2% 28.8% Higher Margin GLPG
Return on Equity (ROE)
Capital Efficiency
-7.4% 10.4% Higher ROE GLPG
52-Week Range Position
Momentum
74% ($0–$11) 23% ($25–$38) Stronger Trend BGM
Beta / 30D Volatility
Risk Regime
3.69β · 80% Vol 0.71β · 20% Vol Lower Realized Risk GLPG
Unified Institutional Score
Composite Signal
59.6 / 100 (HOLD) 61.5 / 100 (BUY) Higher Composite GLPG
Trailing 12M Revenue (USD)
Operating Scale
$48M $602M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
16.9% 56.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.3x EV/Rev N/M PEG · 3.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$9.2M EBITDA ($59.55 Book/Sh · -7.4% ROE) $308M EBITDA ($2.90 Book/Sh · 10.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BGM +2.74 pp
BGM: -1.28% · GLPG: -4.02%
3M Horizon GLPG +59.61 pp
BGM: -76.54% · GLPG: -16.93%
6M Horizon GLPG +85.0 pp
BGM: -97.05% · GLPG: -12.05%
1Y Horizon GLPG +85.0 pp
BGM: -97.05% · GLPG: -12.05%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BGM vs GLPG. Trailing 12-month operating profitability (BGM -23.4% vs GLPG 88.0%) and valuation multiples (BGM N/M vs GLPG N/M Forward P/E) are benchmarked directly in Pillar 4 below.

BGM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$48M
Gross Margin16.9%
Op. Margin-23.4%
ROE / Fwd P/E-7.4% · N/M
GLPG ADR TTM Benchmark FX-Normalized USD
TTM Revenue$602M
Gross Margin56.0%
Op. Margin88.0%
ROE / Fwd P/E10.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BGM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BGM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
GLPG UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 35.2%
IV Percentile 2nd %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact GLPG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BGM Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $108.6M market capitalization and -23.4% operating margin.
OpEx & R&D Reinvestment 40.3% of Rev ($19M)
90D Engineering Disclosures 0 Published
GLPG Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $1.9B market capitalization and 88.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BGM vs GLPG Key Questions & Quantitative Answers

As of Nov 19, 2026, Galapagos NV (GLPG) is the stronger overall head-to-head candidate over BGM Group Ltd. Class A (BGM) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). BGM carries a Unified Composite Score of 59.6/100 (HOLD) at $8.00 (N/M Forward P/E, -23.4% operating margin), whereas GLPG carries 61.5/100 (BUY) at $27.73 (N/M Forward P/E, 88.0% operating margin). Technical & Structure Timing Caution: BGM trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 53.8); meanwhile GLPG is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

GLPG leads the Growth & Scale pillar: BGM posts +69.8% YoY revenue growth and +0.0% YoY earnings growth on $48M TTM revenue (16.9% gross margin, -23.4% operating margin), compared with GLPG at +1093.2% YoY revenue growth and N/A YoY earnings growth on $602M TTM revenue (56.0% gross margin, 88.0% operating margin). On trailing 12-month operating scale, BGM generates $48M in USD-normalized revenue versus $602M for GLPG. In operating R&D and SG&A reinvestment, BGM deploys 40.3% of Rev ($19M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GLPG.

BGM and GLPG trade at balanced relative valuation multiples. BGM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.3x EV/Revenue (-19.3% EBITDA margin), whereas GLPG trades at N/M Forward P/E, 5.1x Trailing P/E, N/M PEG, and 3.2x EV/Revenue (51.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BGM (-7.4% ROE) versus GLPG (10.4% ROE) capital efficiency.

In options market volatility and institutional positioning, BGM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (3.69β · 80% Vol realized risk). By comparison, GLPG carries 35.2% implied volatility (2nd %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.71β · 20% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.